Array BioPharma Announces Positive Top-Line Results from Part 2 of the Phase 3 COLUMBUS Study of Binimetinib and Encorafenib for BRAF-Mutant Melanoma
Go back to Array BioPharma Announces Positive Top-Line Results from Part 2 of the Phase 3 COLUMBUS Study of Binimetinib and Encorafenib for BRAF-Mutant Melanoma| Array Biopharma, Inc. (NASDAQ: ARRY) | Delayed: 5.32 -0.23 (4.14%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.55 | 52 Week High | $7.27 | |||
| Open | $5.51 | 52 Week Low | $2.39 | |||
| Day High | $5.51 | P/E | N/A | |||
| Day Low | $5.31 | EPS | $-0.61 | |||
| Volume | 6,159,329 | |||||
